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Abstract
DNA damage-induced apoptosis suppressor (DDIAS) promotes the progression of lung cancer and hepatocellular
carcinoma through the regulation of multiple pathways. We screened a chemical library for anticancer agent(s)
capable of inhibiting DDIAS transcription. DGG-100629 was found to suppress lung cancer cell growth through the
inhibition of DDIAS expression. DGG-100629 induced c-Jun NH(2)-terminal kinase (JNK) activation and inhibited
NFATc1 nuclear translocation. Treatment with SP600125 (a JNK inhibitor) or knockdown of JNK1 restored DDIAS
expression and reversed DGG-100629-induced cell death. In addition, DGG-100629 suppressed the signal transducer
and activator of transcription (STAT3) signaling pathway. DDIAS or STAT3 overexpression restored lung cancer cell
growth in the presence of DGG-100629. In a xenograft assay, DGG-100629 inhibited tumor growth by reducing the
level of phosphorylated STAT3 and the expression of STAT3 target genes. Moreover, DGG-100629 inhibited the growth
of lung cancer patient-derived gefitinib-resistant cells expressing NFATc1 and DDIAS. Our findings emphasize the
potential of DDIAS blockade as a therapeutic approach and suggest a novel strategy for the treatment of gefitinib-
resistant lung cancer.
Introduction
Lung cancer is a leading cause of cancer mortality
worldwide and constitutes a heterogeneous group of
tumors1. Non-small cell lung cancer (NSCLC) accounts
for 80–85% of all lung cancers and is the most prevalent
subtype2. Current treatments include surgery, platinum-
based chemotherapy, targeted therapy, and immu-
notherapy. However, the prognosis is poor, and the 5-year
survival rate is less than 20%2.
DNA damage-induced apoptosis suppressor (DDIAS) is
aberrantly expressed in human lung cancer, colon cancer,
and hepatocellular carcinoma3,4. The level of DDIAS
expression is correlated with clinical progression and
predicts poor survival in patients with hepatocellular
carcinoma and lung cancer3,5. DDIAS is involved in the
resistance of lung cancer to DNA-damaging agents, such
as cisplatin and camptothecin, as well as in the resis-
tance of lung cancer and hepatocellular carcinoma to
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)3,4,6,7. DDIAS is induced by nuclear factor of
activated T cells (NFATc)1 and myocyte enhancer-
binding factor 2B (MEF2B) and is posttranslationally
regulated by the E3 U-box ubiquitin ligase CHIP6,8,9. In
addition, DDIAS promotes cell proliferation through the
p38-ATF2 pathway in breast cancer cells and interacts
with DNA polymerase, promoting tumorigenesis in
hepatocellular carcinoma3,10. Recently, we reported that
DDIAS promotes STAT3 signaling by directly binding to
STAT3, thus preventing its interaction with PTPRM and
causing increased STAT3 phosphorylation11. Moreover,
we determined that miconazole inhibits the DDIAS/
STAT3 interaction, resulting in anticancer activity in lung
cancer12. Therefore, DDIAS may be a therapeutic target,
and specific DDIAS-targeting agents should be developed.
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Quinoxalines are well-known heterocyclic compounds
bearing a benzene ring and a pyrazine ring. Diversely sub-
stituted quinoxalines and their derivatives exhibit important
therapeutic activities as anticancer, anti-inflammatory, anti-
microbial, and antidepressant agents. A novel series of
ethyl 3-(arylethynyl)quinoxaline-2-carboxylates, indeno
[1,2-b] quinoxaline derivatives, sulfonamide quinoxaline,
and quinoxaline-derived chalcones exhibit anticancer
activity13–16. In addition, 2,3,6-trisubstituted quinoxaline
derivatives and 3-arylethynyl-substituted thieno[3,4-b]-
pyrazine derivatives were identified as Wnt2/β-catenin
pathway inhibitors and transglutaminase 2 inhibitors in
NSCLC and renal cancer cells, respectively17,18.
Previously, we demonstrated that the transcription of
DDIAS is regulated by binding of NFATc1 to the DDIAS
promoter. In this study, a reporter assay based on DDIAS
promoter-controlled transcription was used to screen a
chemical library for DDIAS-targeting anticancer agents. We
report that the quinoxaline derivative DGG-100629 was able
to suppress DDIAS transcription. In particular, DGG-
100629 suppressed the nuclear translocation of NFATc1
through JNK activation, resulting in inhibition of DDIAS
expression and STAT3 signaling. These findings suggest
that NFATc1 functionally links the immune system to
DDIAS and STAT3-mediated oncogenic signaling, which in




An innovative drug library (1500 compounds) was pro-
vided by Dongguk University as 5mM stock solutions.
DGG-100629, DGG-100647, and DGG-108632, synthe-
sized by Prof. Gong, were suspended in dimethyl sulfoxide.
Sulforhodamine B was obtained from Sigma-Aldrich (St.
Louis, MO, USA). SP600125 and CHIR99021 were pur-
chased from Selleckchem (Houston, TX, USA). The fol-
lowing antibodies were used: anti-DDIAS (HPA038540)
from Atlas Antibodies (Stockholm, Sweden); anti-NFATc1
(sc-7294), anti-NFATc2 (sc-7295), anti-NFATc4 (13036),
anti-PARP (7150), anti-HDAC1 (sc-6298), anti-GFP (sc-
9996), and anti-HA (sc-805) from Santa Cruz Biotechnol-
ogy (Dallas, TX, USA); anti-STAT3 (#9139, #4904), anti-
NFATc3 (#4998), anti-p-JNK (#9251), anti-JNK (#9252),
anti-pGSK3β (#9336), anti-GSK3β (#9315), anti-HA
(#3724), anti-Bcl-xL (#2762), anti-pSTAT3 (Y705, #9145),
anti-Caspase-3 (#9662), and anti-Survivin (#2803) from
Cell Signaling Technology (Beverly, MA, USA); anti-
GAPDH (LF-P-A0212) from AbFrontier (Seoul, Korea);
and anti-Flag (F1804) from Sigma-Aldrich.
Flag-DDIAS and STAT3-tagged hemagglutinin (HA)
and the P3 and P5 fragments of the DDIAS promoter
were previously described6,11. The P3 fragment of the
DDIAS promoter (pGL4-P3) was subcloned into pGL4.17,
which contained the sequence of a neomycin resistance
gene as a selection marker (Promega, Madison, WI, USA).
GFP-NFATc1 (#24219) was obtained from Addgene
(Cambridge, MA, USA). The constructs were confirmed
by sequence analysis.
Cell culture and transfection
Human cervical cancer HeLa cells, as well as non-small
cell lung cancer NCI-H23, NCI-H1703, NCI-H358, and
Calu-3 cells, were purchased from the Korean Cell Line
Bank (Seoul, Korea) or KRIBB Cell Line Bank (Daejeon,
Korea). The lung cancer cell lines YL01, YL03, YL05
(EGFR exon19del), and YL08 (EGFR wild-type/ALK
mutation-positive), each derived from a different patient,
were provided by the Yonsei University College of Medi-
cine, Seoul, Korea. Patient characteristics and treatments
were previously described19. Cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) or RPMI-1640
medium supplemented with 10% fetal bovine serum (FBS)
and penicillin/streptomycin (Invitrogen, Carlsbad, CA,
USA). Cells were transfected with plasmids using Turbo-
fect (Thermo Scientific, Rockford, IL, USA) and with
siRNAs (20–40 nM) by electroporation (Neon, Invitrogen)
according to the manufacturer’s instructions. The siRNAs
used in this study were purchased from Bioneer Cor-
poration (Daejeon, Korea). The target sequences were as
follows: siJNK1 #1, 5′-CUGGUAUGAUCCUUCUGAA-3′;
siJNK1 #2, 5′-GUCACACCUGGAAACCUGA-3′; and
siScrambled, 5′-CCUACGCCACCAAUUUCGU-3′.
Establishment of a stable cell line containing the human
DDIAS promoter
HeLa cells were transfected with the P3 fragment (pGL4-
P3) of the DDIAS promoter and selected with 1mg/mL
G418 for 10 days. The selected clones were picked and
cultured with 1mg/mL G418. Each clone was analyzed by a
luciferase reporter assay, and one clone was used in
this study.
Cell growth assay and IncuCyte system
We performed a cell growth inhibition assay by treating
cells (3000 cells/96-well plate) for 72 h with DGG-100629
and calculated the GI50 (half-maximal cell growth inhibi-
tory concentration). Cell growth was determined by using a
sulforhodamine B assay, as previously described20. Cell
death was analyzed with CellPlayer reagent-based annexin
V staining according to the manufacturer’s protocols
(Essen Bioscience, Ann Arbor, MI, USA). Green or red
fluorescence and phase contrast images were acquired
using a ×10 objective.
Luciferase reporter assay
Stable HeLa cells were treated with the compounds for
9 h and lysed with 1× passive lysis buffer in 48-well plates.
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For transient transfection, HeLa cells were cotransfected
with 300 ng of pGL2, pGL2-P3, or pGL2-P5 and 10 ng of
pRL-TK (thymidine kinase promoter-Renilla luciferase
reporter plasmid) by using 2 μL of Turbofect (Thermo
Scientific) per well. Twenty-four hours after transfection,
the cells were treated with the compounds for 9 h and
lysed. Firefly and Renilla luciferase activities were eval-
uated using a dual-luciferase reporter assay system (Pro-
mega) and a luminometer (Victor X light, Perkin Elmer,
Waltham, MA, USA). Firefly luciferase activity was nor-
malized to Renilla luciferase activity and expressed as
relative luciferase activity (RLA), indicating the level of
promoter transcription.
Reverse transcription-polymerase chain reaction
Two micrograms of total RNA was isolated using
TRIzol (Invitrogen) and reverse transcribed into cDNA by
using a TOPscript RT kit (Enzynomics, Daejeon, Korea)
according to the manufacturer’s protocol. The primers
used were as follows: DDIAS F, 5′-CTTGCAGCAGTT
GTTACGAA-3′ and R, 5′-GTGACCAAGCACTTCGA
GTT-3′; GAPDH: 5′-CCUACGCCACCAAUUUCGU-3′.
All reactions were performed in triplicate and normalized
to the level of GAPDH as the internal control.
Immunoblot analysis
DDIAS protein expression was examined at 24 h (2 ×
105 cells/6-well plate) after DGG-100629 treatment.
Cells were lysed with 0.5% NP40 or 1× RIPA buffer
(Millipore, Temecula, CA, USA) containing 1 mM
Na3VO4, 1 mM sodium fluoride, 1 mM PMSF, and
protease inhibitor cocktail (Roche, Basel, Switzerland).
Protein concentrations in the lysates were quantified
using a BCA assay kit (Bio-Rad, Hercules, CA, USA).
Nuclear extracts were prepared as previously descri-
bed21. The lysates were subjected to immunoblotting
with specific antibodies. Western blot band signals were
detected with an enhanced chemiluminescence (ECL)
kit (Millipore).
Chromatin immunoprecipitation assay
ChIP assays were performed by using an EZ-ChIP kit
(Millipore, Billerica, MA, USA) according to the manu-
facturer’s instructions. Chromatin was sheared by sonica-
tion on ice. The chromatin solution was incubated with 2 μg
of an anti-NFATc1 antibody or normal mouse immu-
noglobulin G (IgG; negative control; Santa Cruz Bio-
technology) overnight at 4 °C. These isolated DNA
fragments were used as templates for PCR analysis. The
following primers were used to amplify the NFAT con-
sensus binding sites located in the DDIAS promoter region,
as previously described6: forward for a, 5′-TGCTAGCC
CCTAGGACAGCGC-3′ and reverse, 5′-TCCCCGACAG
GTGGATCAGTA-3′; forward for b, 5′-TACGCCCAGGA
GGCTCAGCGAA-3′ and reverse, 5′-CCGCGTCCTTTT
CCGCCGGAA-3′. All ChIP experiments were performed at
least twice.
Mouse xenograft assay
All mouse studies were conducted in accordance with a
protocol approved by the Institutional Animal Care and
Use Committee. Tumors were established by injecting
NCI-H1703 cells (9 × 106 cells/mouse) subcutaneously
into 6-week-old BALB/c female nude mice (Nara Biotech.,
South Korea). Tumor volumes were estimated by the
following formula: length (mm) × width (mm) × height
(mm)/2. When the average tumor volume was 57.5 cm3,
the mice were randomly divided into two groups (n= 5
mice/group), and DGG-100629 (10 mg/kg) was adminis-
tered intraperitoneally once a day for 18 days. The mice
were euthanized on day 18, and the tumor weights were
measured.
Statistical analysis
All data were obtained from at least three independent
experiments. The results are expressed as the mean ± S.E.
M. values. Statistical analyses were performed by using a
two-tailed Student’s t-test. P values < 0.05 were con-
sidered significant.
Results
Screening and identification of inhibitors of DDIAS
expression
To search for drugs capable of inhibiting DDIAS
expression, HeLa cells (HeLa-pGL4-P3) stably expres-
sing the luciferase reporter gene under the control of the
DDIAS promoter (P3, −1205/+125) were established
(Fig. 1a). A total of 1500 compounds from an innovative
drug library provided by Dongguk University were
screened for their ability to inhibit HeLa-pGL4-P3 cell
growth. Of these compounds, 53 that suppressed the
growth of HeLa-pGL4-P3 cells by more than 50% at
5 μM but did not affect the growth of WI-38 normal
human lung fibroblasts were selected (data not shown).
Then, the effect of these 53 compounds on DDIAS
promoter activity was examined. Notably, three com-
pounds, DGG-108632, DGG-100629, and DGG-100647,
inhibited DDIAS promoter activity by more than 60% at
5 μM (Fig. 1a). The three compounds, which shared a
2,3,4-trisubstituted quinoxaline scaffold (Fig. 1b), were
more effective at inhibiting DDIAS promoter activity
than cyclosporine A (CsA), an inhibitor of calcineurin
that also suppresses DDIAS expression6. Next, the effect
of DGG-108632, DGG-100629, and DGG-100647 on
cell growth was examined. DGG-100629 displayed a
lower GI50 value (GI50= 0.41 μM) than both DGG-
108632 (GI50= 3.07 μM) and DGG-100647 (GI50=
1.95 μM) (Fig. 1c) and did not affect the growth of
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WI-38 cells (Supplementary Fig. 1). DGG-108632
and DGG-100629 decreased the mRNA and protein
levels of DDIAS in a dose-dependent manner (Fig. 1d, e).
These data suggested that DGG-100629 suppressed
the growth of cancer cells by inhibiting DDIAS
transcription.
NFATc1 was required for DGG-100629-induced
suppression of DDIAS expression
Since DGG-100629 was by far the most potent inhi-
bitor of cancer cell growth among the three identified
compounds, it was selected for further experiments. We
previously demonstrated that binding of NFATc1 to a
region of the DDIAS promoter located 350 bp upstream
of the transcription start site is crucial for the regulation
of DDIAS transcription6. To investigate the molecular
mechanism by which DGG-100629 represses DDIAS
transcription, the role of the NFAT element (i.e., the
NFATc1-binding site) in the DDIAS promoter was
explored by luciferase reporter assays in the presence of
DGG-100629. DGG-100629 clearly inhibited the luci-
ferase activity of both the P3 (−1205 base pair) and P5
(−350 base pair) DDIAS promoter fragments (Fig. 2a),
indicating that the NFAT element plays a role in the
DGG-100629-induced suppression of DDIAS transcrip-
tion (Supplementary Fig. 2).
The role of NFAT signaling in DGG-100629-induced
DDIAS suppression was further examined. DGG-100629
did not change the protein levels of NFATc1, NFATc2,
NFATc3 or NFATc4 (Fig. 2b). A subcellular fractionation
assay showed that DGG-100629 promoted the relocali-
zation of NFATc1 from the nucleus to the cytoplasm (Fig.
2c). Moreover, a chromatin immunoprecipitation (ChIP)
assay revealed that endogenous NFATc1 was recruited to
the proximal DDIAS promoter region containing the
NFAT binding sites and that DGG-100629 inhibited this
recruitment (Fig. 2d). As expected, DGG-100629 sup-
pressed the nuclear translocation of exogenous NFATc1
(Fig. 2e). However, NFATc1 overexpression slightly
reversed the reduction in DDIAS expression (Fig. 2f).
Collectively, these findings indicated that DGG-100629
suppressed DDIAS transcription by preventing NFATc1
translocation to the nucleus and, therefore, its recruit-
ment to the DDIAS promoter.
DGG-100629 inhibited the NFATc1/DDIAS pathway
through the activation of JNK
Since a role of NFATc1 in the regulation of DDIAS
expression in human lung cancers was previously
demonstrated6, we explored the impact of DGG-100629
on NFATc1-regulated DDIAS expression in lung cancer
cells. Western blot analysis showed that NFATc1 and
Fig. 1 Screening of suppressors of DDIAS expression. a HeLa-pGL4-P3 cells were treated with the compounds (5 μM) for 9 h. Cell lysates were
analyzed by luciferase reporter assays. Cyclosporine A (CsA) was used as the positive control. The DDIAS promoter P3 fragment was located 1205 bp
upstream of the luciferase gene (upper panel). b Structures of three selected compounds. c HeLa cells were treated with the compounds for 72 h.
Cell growth was evaluated by a sulforhodamine B (SRB) assay. d Assessment of DDIAS mRNA levels by quantitative RT-PCR in HeLa cells treated for
12 h with the compounds. e Western blot analysis of DDIAS protein levels in HeLa cells treated with the compounds for 24 h.
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DDIAS protein levels were higher in NCI-H23 (H23) and
NCI-H1703 (H1703) cells than in NCI-H358 (H358) and
Calu-3 cells (Fig. 3a). In addition, H23 and H1703 cells
exhibited increased sensitivity to DGG-100629 (3.2-fold
lower GI50) compared with H358 and Calu-3 cells
(Fig. 3b). Nuclear export of NFATc1 is followed by its
phosphorylation by glycogen synthase kinase-3β (GSK3β)
or c-Jun NH(2)-terminal kinase (JNK) and by suppression
of its transcriptional activity22,23. Notably, DGG-100629
was found to induce the activation of both GSK3β and
JNK (Fig. 3c). Moreover, SP600125 (a JNK inhibitor) but
not CHIR99021 (a GSK3β inhibitor) restored cell death
and suppressed DDIAS promoter activity in the presence
of DGG-100629 (Fig. 3d–f). Furthermore, JNK1 silencing
by a specific siRNA reversed DGG-100629-induced DDIAS
downregulation and restored cell death (Fig. 3g, h).
These results suggested that DGG-100629 suppressed
DDIAS expression and cell growth by regulating JNK/
NFATc1 signaling in NSCLC.
DDIAS downregulation was involved in DGG-100629-
induced apoptosis
We examined whether DGG-100629 caused apoptotic
changes in lung cancer cells. DGG-100629 induced the
cleavage of PARP and caspase-3, which was accompanied
by a decrease in the DDIAS protein level (Fig. 4a). How-
ever, SP600125 blocked DGG-100629-induced cleavage of
PARP and caspase-3 (Fig. 4b). Moreover, overexpression
of Flag-DDIAS abrogated the inhibitory effect of DGG-
100629 on cancer cell growth (Fig. 4c).
We previously reported that DDIAS promotes STAT3
tyrosine phosphorylation by inhibiting PTPRM and that
DDIAS expression correlates with STAT3 phosphoryla-
tion in human lung cancer11. In the current study, we
confirmed that DGG-100629 treatment decreased STAT3
phosphorylation, as well as the expression of the STAT3
targets Bcl-xL and survivin (Fig. 4d). In addition, HA-
STAT3 overexpression attenuated DGG-100629-induced
cell death, as well as PARP and caspase-3 activation (Fig.
4e, f). Moreover, STAT3 overexpression rescued cells
from DGG-100629-induced cell death, as shown by
annexin V staining (Fig. 4g). These results suggested
that DGG-100629-induced DDIAS downregulation was
required for the suppression of STAT3 activation and the
promotion of apoptosis in NSCLC cells.
DGG-100629 inhibited tumor growth in a mouse xenograft
model
To investigate the effect of DGG-100629 on tumor
growth, a xenograft assay using H1703 cells was carried
out. DGG-100629 (10 mg/kg) was administered to mice
by intraperitoneal injection. DGG-100629-treated mice
did not show significant changes in body weight (Fig. 5a),
while they exhibited reductions of 34.8% and 35.3% in
Fig. 2 DGG-100629 inhibited DDIAS expression. a HeLa cells were cotransfected with DDIAS promoter-containing luciferase reporter plasmids (P3,
P5, pGL2) and control plasmids (pRL-TK) and were then treated with DGG-100629 (2 μM) for 9 h. b Western blot analysis of cells treated with DGG-
100629 for 6 h. c Fractionation assay in cells treated with DGG-100629 for 6 h. d ChIP assay in cells treated with DGG-100629 (2 μM) for 9 h. e, f HeLa
cells were transfected with GFP-NFATc1 for 24 h and were then treated with DGG-100629 (2 μM) for 6 h (e) or 24 h (f). e Assessment of GFP-NFATc1
localization by visualization of green fluorescence with the IncuCyte system. Scale bar, 20 μm. f DDIAS expression in cells overexpressing GFP-NFATc1.
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tumor volume and weight, respectively (Fig. 5b, c).
Western blot analysis of resected tumors revealed that
the protein levels of DDIAS and the STAT3 targets
survivin and Bcl-2 were dramatically decreased in DGG-
100629-treated tumors compared to vehicle-treated
tumors (Fig. 5d). An in vivo xenograft assay demon-
strated that the anticancer activity of DGG-100629 was
associated with reduced STAT3 phosphorylation and
downregulated expression of STAT3 target genes.
Moreover, JNK activation by DGG-100629 inhibited the
nuclear translocation of NFATc1, which resulted in
DDIAS downregulation as well as inactivation of the
STAT3 signaling pathway (Fig. 5e).
DGG-100629 inhibited the growth of gefitinib-resistant
lung cancer
Among NSCLC cell lines, H358 and Calu-3 cells are
sensitive to gefitinib, while H23, H1299, and H1703 cells
are resistant to gefitinib24. We observed that H23 and
H1703 cells, which express high levels of DDIAS, were
sensitive to DGG-100629. Therefore, patient-derived lung
cancer cells (PDCs) were used to verify whether DGG-
100629 could be a suitable therapeutic option for patients
with gefitinib-resistant lung cancer. Therefore, the effect
of DGG-100629 on the growth of various lines of
gefitinib-resistant PDCs (YL01, YL03, YL05, and YL08)
was examined. PDCs exhibited high levels of NFATc1,
DDIAS, and activated STAT3 (Fig. 6a). Consistent with a
previous report19, all tested PDC lines showed resistance
to gefitinib, as indicated by a GI50 > 10 μM (Fig. 6b).
However, DGG-100629 suppressed PDC growth at low
micromolar concentrations (Fig. 6b, c). In addition, DGG-
100629 inhibited the expression of DDIAS and STAT3
targets and promoted the death of YL05 (EGFR exon19-
del) and YL08 (wild-type EGFR, ALK mutation-positive)
cells (Fig. 6d). These results suggested that NFATc1 and
DDIAS in cancer cells contribute to high STAT3 levels
and resistance to gefitinib and that DGG-100629 induces
PDC apoptosis by downregulating DDIAS expression and
suppressing STAT3 signaling.
Discussion
Here, we identified DGG-100629 as a drug for the
treatment of lung cancer via its suppression of DDIAS
expression and inactivation of STAT3 signaling. DGG-
100629 activated JNK, thereby preventing NFATc1
Fig. 3 DGG-100629 activated JNK. a Expression of NFATc1 and DDIAS in NSCLC cells. b Cell growth assay in cells treated with DGG-100629 (0.5 μM).
c Activation of JNK and GSK3β in H1703 cells treated with DGG-100629 for 6 h. d–f H1703 cells were treated with SP600125 (5 μM) and CHIR99021
(5 μM) in the presence of DGG-100629 (2 μM), and luciferase assays (d), western blotting with quantitative analysis (e), and cell growth assays (f) were
performed. gWestern blotting with quantitative analysis and h cell growth assay in H1703 cells transfected with siJNK1 for 24 h and then treated with
DGG-100629 (2 μM) for 24 h. The data were obtained from triplicate experiments. The values shown are the mean±SEM values. *p < 0.05, **p < 0.01,
***p < 0.001.
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translocation to the nucleus and inhibiting the expression
of DDIAS and STAT3 target genes, such as Bcl-xL and
survivin. DGG-100629 displayed effective anticancer
activity, both in vitro and in vivo, in lung cancer cells
expressing high levels of NFATc1 and DDIAS and exhi-
biting gefitinib resistance.
We previously reported that NFATc1 but not NFATc2-
4 is involved in DDIAS transcription6. Using siRNAs
against NFATc1-4, we showed that NFATc1 regulates the
promoter activity and mRNA level of DDIAS. In addition,
NFATc1 but not NFATc2 is recruited to the promoter
region of DDIAS, and its overexpression increases DDIAS
expression. NFATc1 is an oncogene implicated in many
cancers25,26. NFATc1 is highly expressed in lung cancer
and promotes lung cancer cell survival and epithelial-
mesenchymal transition6,27. Moreover, by promoting the
expression of multiple target genes, including DDIAS,
cyclin D1, IL-2, and IL-4, NFATc1 protects lung cancer
cells against anticancer drug-induced death6,28. The
transcriptional activity of NFATc1 is regulated by phos-
phorylation, which influences its nucleocytoplasmic dis-
tribution. NFATc1 activity is regulated by a variety of
kinases. PIM1 promotes NFATc1 activity and stabi-
lity29,30, while DYRK1a, GSK3β, and JNK inhibit NFATc1
transcriptional activity22,23,31. The present study demon-
strated that DGG-100629 activated JNK, which in turn
induced NFATc1 phosphorylation and cytoplasmic
translocation, ultimately suppressing DDIAS transcrip-
tion. Notably, GFP-NFATc1 overexpression did not sig-
nificantly alter the effect of DGG-100629 on DDIAS
expression (Fig. 2f), implying that the intracellular loca-
lization of NFATc1, rather than its protein level, is crucial
for DDIAS transcription.
Quinoxaline derivatives have been reported to activate
the JNK and p38 MAPK pathways, resulting in cancer cell
death32–34. Consistent with previous findings, we found
that DGG-100629 induced JNK phosphorylation and that
both transcriptional and pharmacological suppression of
JNK reversed DGG-100629-induced DDIAS down-
regulation and restored cancer cell growth (Fig. 3).
Notably, a previous study demonstrated that quinoxaline
derivatives of DGG-100629 inhibit the Wnt/β-catenin
pathway, leading to a decrease in the β-catenin protein
level18, which is believed to be associated with the phe-
notype of DDIAS knockdown9. Even though the lead
compound has the same core skeleton of as previous
research targets, the lead compound with the most
potent targeted activity toward DDIAS transcription,
Fig. 4 DDIAS and STAT3 overexpression prevented DGG-100629-induced lung cancer cell death. a Western blot analysis of H1703 cells
treated with DGG-100629 for 24 h. b Western blot analysis of cells treated with SP600125 (5 μM) and DGG-100629 (2 μM). c Western blot analysis and
growth of H1703 cells transfected with Flag-DDIAS and treated with DGG-100629 (2 μM). dWestern blot analysis of cells treated with DGG-100629 for
24 h. e, f STAT3 overexpression after HA-STAT3 transfection prevented the apoptosis induced by DGG-100629 (2 μM). g Annexin V staining with the
IncuCyte system. The scale bars represent 100 μm. The data were obtained from triplicate experiments. The values shown are the mean±SEM values.
*p < 0.05, **p < 0.01.
Im et al. Experimental & Molecular Medicine (2021) 53:643–653 649
Official journal of the Korean Society for Biochemistry and Molecular Biology
DGG-100629, has a building block chemical structure (2-
ethoxy ethyl amine group) quite different from that of the
previous targets in NSCLC or the Wnt2/β-catenin path-
way (2-ethoxy amine group). The piperazine side chain at
the 2-position is much longer than that of the previous
research targets. On the other hand, additional effects of
DGG-100629 on cell survival may not be excluded. We
assumed that the relatively poor efficacy of DGG-100629
in vivo may be due to its low microsomal stability and
poor pharmacokinetic properties (Supplementary Fig. 3).
Further structural modifications may be needed to
improve the pharmacokinetic profile and in vivo efficacy
of DGG-100629.
High expression of NFATc1 and DDIAS was previously
found to be associated with drug resistance in lung can-
cer6,28. Interestingly, we found that the expression of
NFATc1 and DDIAS was elevated in H23 and H1703
cells, as well as in four gefitinib-resistant PDCs, but was
downregulated in gefitinib-sensitive lung cancer cells,
such as H358 and Calu-3 cells (Figs. 3a; 6a, c; and Sup-
plementary Fig. 4). DGG-100629 markedly inhibited the
proliferation of gefitinib-resistant PDCs, as well as H23
and H1703 cells. Our data may suggest a novel strategy
for the treatment of gefitinib-resistant lung cancers with
high expression of NFATc1 and DDIAS.
Elevated DDIAS expression promotes STAT3 activity11.
In human lung cancer cells and tissues, DDIAS expression
is strongly correlated with the level of phospho-STAT3
Y705, which supports the role of STAT3 phosphorylation
in lung tumorigenesis11. DGG-100629 reduced the levels
of total and phosphorylated STAT3 but not its mRNA
level (Fig. 4d and Supplementary Fig. 5). Since DGG-
100629 caused DDIAS downregulation, the impact of
DDIAS knockdown on STAT3 protein expression and
phosphorylation was examined. In fact, DDIAS knock-
down by two different siRNAs reduced the STAT3 pro-
tein level in both H23 and H1703 cells (Supplementary
Fig. 6). The DDIAS protein level was previously found to
Fig. 5 DGG-100629 suppressed tumor growth in vivo. a–c Body weight and tumor growth inhibition in the mouse xenograft assay. NCI-H1703
cells (9 × 106 cells/mouse) were injected into BALB/c nude mice. DGG-100629 (10 mg/kg) was injected into tumors five times at 2-day intervals after
the tumors reached an average volume of 77 mm3. Tumor volume data are shown (n= 5 mice/group; *p < 0.05, **p < 0.01). d DGG-100629 reduced
the protein level of STAT3 and its targets in vivo, as determined by Western blotting. e Proposed model for the anticancer activity of DGG-100629.
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correlate with both the total and phosphorylated STAT3
(phospho-STAT3 Y705) levels in lung cancer cell lines11.
However, DDIAS knockdown suppressed STAT3 Y705
phosphorylation but did not affect the total protein level
of STAT3 in the presence of IL-6 stimulation. The level of
STAT3 might be regulated by different mechanisms
depending on the cellular context. STAT3 was reported to
be regulated by posttranslational modifications such as
phosphorylation, acetylation, oxidation, and ubiquitina-
tion35–38. PDLIM2, Fbw7, and constitutive photo-
morphogenic 1 (COP1) were identified as E3 ligases for
STAT3 in T helper 17 cells, diffuse large B-cell lymphoma
(DLBCL) cells, and prostate cancer cells, and several
proteins, including TMF/ARA160, are involved in pro-
teasomal STAT3 degradation39–43. In addition, TRAF6
mediates K63-linked polyubiquitination of STAT3, thus
repressing its transcriptional activity, independent of
STAT3 degradation37. Monoubiquitination of STAT3 at
K97 enhances the expression of antiapoptotic genes by
promoting the formation of the bromodomain-containing
protein 4 (BRD4) complex44. Further studies are needed
to confirm the role of DDIAS in the regulation of STAT3
protein stability and in the ubiquitin-proteasome system.
We suggest that DDIAS-targeting agents may be sui-
table for the personalized treatment of patients with high
DDIAS/STAT3 expression. Our data provide mechanistic
insights into the tumorigenic effects of DDIAS, linking
NFATc1 function in immune cells to the role of STAT3 in
the proliferation and survival of lung cancer cells. Finally,
our findings suggest an alternative strategy for the man-
agement of gefitinib-resistant lung cancers with high
DDIAS expression.
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